OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Review of Vaccines is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Respiratory syncytial virus infection and the need for immunization in Korea	182
Estimating the lifetime cost of vaccination in 23 European Countries: a modeling study	153
Safety profile of COVID-19 vaccines, preventive strategies, and patient management	134
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy	85
The influence of selected factors on the immunogenicity of preventive vaccinations against hepatitis A, B and influenza in solid organ transplant recipients undergoing immunosuppressive therapy – a re	80
Plasmodiuminfection and drug cure for malaria vaccine development	79
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant	65
Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?	64
Immunization in state of siege: the importance of thermostable vaccines for Ukraine and other war-torn countries and territories	64
Nonhuman primate models for evaluation of SARS-CoV-2 vaccines	62
Challenges in vaccine transport: can we deliver without the cold chain?	56
Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses	56
Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study	55
Response to: letter to “Self-controlled case series design in vaccine safety: a systematic review”	55
Immunogenicity and safety of a high-dose and prolonged-schedule hepatitis B vaccine among chronic kidney disease patients: a randomized, parallel-controlled trial	54
Further implications on the global real-world vaccine effectiveness against SARS-CoV-2	50
Overcoming scientific barriers in the transition fromin vivoto non-animal batch testing of human and veterinary vaccines	49
COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study	48
No association between enterovirus 71 (EV71) vaccination and risk of febrile seizures: a population-based near real-time surveillance study	48
Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China	47
Estimating the time required to reach HPV vaccination targets across Europe	44
Eradicating polio in Pakistan: a systematic review of programs and policies	41
A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019)	41
Pneumococcal vaccine implementation in the African meningitis belt countries: the emerging need for alternative strategies	40
The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines	39

A review of data systems for assessing the impact of HPV vaccination in selected high-income countries	37
Immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population	37
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?	36
Global prevalence of acceptance of COVID-19 vaccines and associated factors in pregnant women: a systematic review and meta-analysis	34
Effectiveness of pneumococcal vaccination on hospitalization and death in the adult and older adult diabetic population: a systematic review	33
Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a revi	33
Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis	32
Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis	32
Understanding immunity to influenza: implications for future vaccine development	32